Loading
Every dated change on the records linked to Smouldering multiple myeloma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Subcutaneous daratumumab delayed progression to active myeloma or death compared with active monitoring in high-risk smouldering myeloma; approved in the United States in 2025.
A milestone in how this cancer is treated.